【摘要】 目的 :探讨子宫肌瘤中血管内皮生长因子 ( VEGF)和微血管密度 ( MVD)的关系及米非司酮治疗子宫肌瘤的机制。方法 :将 40例有症状的子宫肌瘤患者随机分成两组 ,试验组 2 0例 ,于月经周期的分泌早期给予米非司酮治疗 ,剂量为每天 2 5 mg;对照组 2 0例未给任何治疗 ,采用免疫组化的方法对子宫肌瘤中血管内皮生长因子和微血管密度进行半定量的分析。结果 :血管内皮生长因子及微血管密度在子宫肌瘤中有显著的正相关性 ( r=0 .869,P<0 .0 1)。治疗组较对照组血管内皮生长因子及微血管密度均有明显下降 ( P<0 .0 5及 P<0 .0 1)。结论 :子宫肌瘤中血管内皮生长因子与其血管生成关系密切 ,米非司酮通过抑制子宫肌瘤中血管内皮生长因子的表达 ,从而减少肌瘤血液供应 ,抑制其生长 ,改善其临床症状更多还原

【Abstract】 Objective: To study the relationship of vascular endothelial growth factor (VEGF) and microvascular density (MVD) in uterine leiomyomas and therapeutic effect of Mifepristone. Methods: 40 patients, who had uterine leiomyomas and had symptom such as menorrhugia, were randomly divided into two groups, 20 patients in treat group were treated with 25 mg Mifepristone daily beginning on the early secrstory phase of the menstrual cycle for a period of seven days. All leiomyomas were determined VEGF levels, and MVD semiquantitatively by immunochemical method. Results: There was a close positive correlation between VEGF expression and MVD ( r=0.819,P <0.01). VEGF expression and MVD in treat group were lower significantly than those in control group. Conclusion: VEGF is highly related to angiogenesis of uterine leioyoma, Mifepristone can inhibit the growth of leioyomas and improve clinical symptom of leiomyomas by the way of lessening the blood supply of leiomyomas.更多还原